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Burke et al. [1] have recently questioned the necessity of using a direct method of GFR measurement in kidney 
transplant trials suggesting that the predictive performance of the Cockcroft-Gault, Nankivell or the MDRD 
study equations was sufficient to appropriately detect a treatment difference in renal graft function. 
This statement is at odds with many, if not all, of the recent recommendations that have pinpointed the various 
limitations of predicting GFR from serum creatinine value in kidney transplantation [2-4]. 
Burke et al. based their conclusion on the finding that the three equations give a similar difference in mean GFR 
between the two treatment groups of a sirolimus trial. Importantly, as no reference method of GFR measurement 
was used as a comparator, one cannot rule out the possibility that all the three equations give a similar but 
erroneous conclusion. 
In order to directly address the potential dangers of estimating rather than measuring GFR in transplantation 
research protocols, we performed several simulations from a previously described cohort of 500 inulin 
clearances [5]. This cohort was split into two groups of n=250 each, either according to the date of 
transplantation (sorted by chronological order, simulation #1) or according to the recipient's age (sorted by 
increasing age, simulation #2). 
For simulation #1, the mean true GFR significantly differed between the two groups, and so did the mean GFR 
estimated by the MDRD study equation. However, differences were no longer significant when the Cockcroft-
Gault or the Nankivell equations estimated the GFR. In other words, had these equations been used in a 
hypothetical trial reproducing these conditions, the real beneficial effect of the tested therapy might have been 
missed (Table 1). Conversely, in simulation #2, the mean true GFR was not different between the two groups, 
and neither was the mean estimate given by the Nankivell and the MDRD study equations. But here, the 
Cockcroft-Gault equation did give a significant difference between the two groups (Table 2). 
On the same lines, a recent trial has been reported on the effect of a new CTLA4 fusion protein (belatacept) in 
renal transplantation [6]. Among the secondary end-points, the effect on the GFR at 1-year post-transplant has 
been analyzed. Interestingly, while belatacept was found to have a beneficial effect when GFR was measured by 
a reference method (iohexol clearance of 66.3 and 53.5 ml/min/1.73 m2 for the belatacept-based treatment group 
and the cyclosporine A-based treatment group, respectively),    no    significant   difference   was   reported 
between the two groups when GFR was estimated by the MDRD equation (72.4 and 68.0 ml/min/1.73 m2 for 
belatacept and cyclosoprine A group, respectively). 
As stressed by Burke et al., we do acknowledge that using a creatinine-based GFR equation is likely to limit the 
rate of missing GFR values. Still, this has to be balanced with the risk of measuring an endpoint with a non-
optimal method. Moreover, appropriate methodology has been described to efficiently circumvent the problem 
of missing data in this context [7]. 
Finally, we have to keep in mind that some of key clinical trials in nontransplant CKD patients have successfully 
and convincingly incorporated reference methods of GFR measurement to evaluate primary endpoints [8-10]. 
Should not the transplant clinical trials measure up to the same standard of quality? 
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Table 1. Comparison of mean GFR between two fictitious groups of transplant patients (simulation #1). 
 Group A 
mean ± standard deviation 
(ml/min/1.73 m2) 
Group B 




Inulin clearance 45 ± 16 53 ± 22 <0.0001 
MDRD 47 ± 17 52 ± 22 0.014 
Cockcroft-Gault 52 ± 17 54 ± 20 0.125 
Nankivell 56 ± 16 58 ± 20 0.067 
An historic cohort of 500 inulin clearances (true GFR) is split into two groups of 250 clearances each, according to the date of 
transplantation. The difference in mean GFR (either the true GFR or the GFR estimated by different equations) between the two groups is 
evaluated using a Student's t-test. 
 
Table 2. Comparison of mean GFR between two fictitious groups of transplant patients (simulation #2). 
 
Group A 
mean ± standard deviation 
(ml/min/1.73 m2) 
Group B 




Inulin clearance 51 ± 19 47 ± 21 0.119 
MDRD 50 ± 19 49 ± 21 0.668 
Cockcroft-Gault 57 ± 19 48 ± 18 <0.0001 
Nankivell 57 ± 16 57 ± 19 0.978 
An historic cohort of 500 inulin clearances (true GFR) is split into two groups of 250 clearances each, according to the recipient's age. The 
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